Merck discontinues Phase 3 trial of Xevinapant in locally advanced head and neck cancer Ruchika Sharma27 Jun 2024 5:04 PM ISTGermany: Merck, a science and technology company, has announced the discontinuation of the Phase III randomized TrilynX study evaluating...
CDSCO Panel Approves IQVIA's Protocol Amendment Proposal For Anti-cancer Drug Xevinapant Dr. Divya Colin27 March 2024 5:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
